Rothenberg P - Search Results

1

Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study.

Sha S, Polidori D, Farrell K, Ghosh A, Natarajan J, Vaccaro N, Pinheiro J, Rothenberg P, Plum-Mörschel L. Sha S, et al. Among authors: rothenberg p. Diabetes Obes Metab. 2015 Feb;17(2):188-97. doi: 10.1111/dom.12418. Epub 2015 Jan 5. Diabetes Obes Metab. 2015. PMID: 25421015 Free PMC article. Clinical Trial.

2

Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on C-peptide kinetics.

Polidori D, Sha S, Heise T, Natarajan J, Artis E, Wang SS, Vaccaro N, Rothenberg P, Stirban A. Polidori D, et al. Among authors: rothenberg p. Clin Pharmacol Drug Dev. 2015 Jan;4(1):12-7. doi: 10.1002/cpdd.115. Epub 2014 May 28. Clin Pharmacol Drug Dev. 2015. PMID: 27127999 Clinical Trial.

3

Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study.

Polidori D, Sha S, Mudaliar S, Ciaraldi TP, Ghosh A, Vaccaro N, Farrell K, Rothenberg P, Henry RR. Polidori D, et al. Among authors: rothenberg p. Diabetes Care. 2013 Aug;36(8):2154-61. doi: 10.2337/dc12-2391. Epub 2013 Feb 14. Diabetes Care. 2013. PMID: 23412078 Free PMC article. Clinical Trial.

4

Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus.

Polidori D, Sha S, Ghosh A, Plum-Mörschel L, Heise T, Rothenberg P. Polidori D, et al. Among authors: rothenberg p. J Clin Endocrinol Metab. 2013 May;98(5):E867-71. doi: 10.1210/jc.2012-4205. Epub 2013 Apr 12. J Clin Endocrinol Metab. 2013. PMID: 23585665 Free PMC article. Clinical Trial.

5

Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.

Sha S, Devineni D, Ghosh A, Polidori D, Hompesch M, Arnolds S, Morrow L, Spitzer H, Demarest K, Rothenberg P. Sha S, et al. Among authors: rothenberg p. PLoS One. 2014 Aug 28;9(8):e105638. doi: 10.1371/journal.pone.0105638. eCollection 2014. PLoS One. 2014. PMID: 25166023 Free PMC article. Clinical Trial.

6

Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetes.

Katz LB, Gambale JJ, Rothenberg PL, Vanapalli SR, Vaccaro N, Xi L, Sarich TC, Stein PP. Katz LB, et al. Among authors: rothenberg pl. Diabetes Obes Metab. 2012 Aug;14(8):709-16. doi: 10.1111/j.1463-1326.2012.01587.x. Epub 2012 Mar 14. Diabetes Obes Metab. 2012. PMID: 22340428 Clinical Trial.

7

Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects.

Sha S, Devineni D, Ghosh A, Polidori D, Chien S, Wexler D, Shalayda K, Demarest K, Rothenberg P. Sha S, et al. Among authors: rothenberg p. Diabetes Obes Metab. 2011 Jul;13(7):669-72. doi: 10.1111/j.1463-1326.2011.01406.x. Diabetes Obes Metab. 2011. PMID: 21457428 Clinical Trial.

8

CCR2 antagonism in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.

Di Prospero NA, Artis E, Andrade-Gordon P, Johnson DL, Vaccaro N, Xi L, Rothenberg P. Di Prospero NA, et al. Among authors: rothenberg p. Diabetes Obes Metab. 2014 Nov;16(11):1055-64. doi: 10.1111/dom.12309. Epub 2014 May 25. Diabetes Obes Metab. 2014. PMID: 24798870 Clinical Trial.

9

Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus.

Sha S, Polidori D, Heise T, Natarajan J, Farrell K, Wang SS, Sica D, Rothenberg P, Plum-Mörschel L. Sha S, et al. Among authors: rothenberg p. Diabetes Obes Metab. 2014 Nov;16(11):1087-95. doi: 10.1111/dom.12322. Epub 2014 Jul 8. Diabetes Obes Metab. 2014. PMID: 24939043 Clinical Trial.

10

Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus.

Devineni D, Curtin CR, Polidori D, Gutierrez MJ, Murphy J, Rusch S, Rothenberg PL. Devineni D, et al. J Clin Pharmacol. 2013 Jun;53(6):601-10. doi: 10.1002/jcph.88. Epub 2013 May 14. J Clin Pharmacol. 2013. PMID: 23670707 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

72 results

Search Page

Filters